Search all trials

Find therapies in clinical trials near you – page 6

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 961
countries: 28
conditions: 2 103

3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today

Quick filters

C3 glomerulopathy

Recruiting

InvestigationalNo placebo

Study on Long-Term Effects of Iptacopan in Patients with C3 Glomerulopathy or Idiopathic Immune-Complex Membranoproliferative Glomerulonephritis

InvestigationalNo placebo

Greece

Participants:0–17 years · 18–64 years · 65+ years
Substances:Iptacopan

Contact Research Centre

Myelofibrosis

Recruiting

Registered drug

Study on Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis and Suboptimal Response to Ruxolitinib

Registered drug

Greece

Participants:18–64 years · 65+ years
Substances:Navtemadlin

Contact Research Centre

Sepsis

Recruiting

Registered drug

Study on Early Clarithromycin Treatment to Prevent Sepsis in Patients with Community-Acquired Pneumonia

Registered drug

Greece

Participants:18–64 years · 65+ years
Substances:Clarithromycin

Contact Research Centre

Chronic kidney disease+1

Recruiting

InvestigationalNo placebo

Study on the Long-Term Safety of Finerenone with ACE Inhibitors or ARBs for Children and Young Adults with Chronic Kidney Disease and Proteinuria

InvestigationalNo placebo

Greece

Participants:0–17 years · 18–64 years
Substances:Finerenone

Contact Research Centre

Plasma cell myeloma refractory

Recruiting

Registered drugNo placebo

Study Comparing Elranatamab to Drug Combinations for Patients with Relapsed/Refractory Multiple Myeloma After Anti-CD38 Therapy

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Bortezomib

Contact Research Centre

Myelofibrosis+1

Recruiting

Registered drugNo placebo

Study on the Effectiveness and Safety of Selinexor for Patients with Myelofibrosis and Moderate Thrombocytopenia Who Have Not Used JAK Inhibitors

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Aprepitant

Contact Research Centre

Chronic lymphocytic leukaemia+1

Recruiting

Registered drugNo placebo

Study Comparing Nemtabrutinib, Ibrutinib, and Acalabrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Acalabrutinib

Contact Research Centre

Thalassaemia beta+2

Recruiting

InvestigationalNo placebo

Study of SP-420 for Patients with Transfusion-Dependent Alpha or Beta Thalassemia

InvestigationalNo placebo

Greece

Participants:18–64 years
Substances:(S)-4,5-Dihydro-2-[2-Hydroxy-4-(3,6-Dioxaheptyloxy)Phenyl]-4-Methyl-4-Thiazolecarboxylic Acid

Contact Research Centre

Glomerulonephritis membranoproliferative

Recruiting

Investigational

Study on the Effects of Iptacopan in Patients with Idiopathic Membranoproliferative Glomerulonephritis (IC-MPGN)

Investigational

Greece

Participants:0–17 years · 18–64 years
Substances:Iptacopan

Contact Research Centre

Post-acute COVID-19 syndrome

Recruiting

Registered drug

Study on Anakinra for Patients with Long COVID and Ongoing Respiratory Symptoms

Registered drug

Greece

Participants:18–64 years · 65+ years
Substances:Anakinra

Contact Research Centre

Transitional cell cancer of the renal pelvis and ureter

Recruiting

Registered drugNo placebo

Study of Sacituzumab Govitecan for Patients with Advanced or Metastatic Bladder Cancer

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Avelumab

Contact Research Centre

Double hit lymphoma+7

Recruiting

Registered drugNo placebo

Study on Acalabrutinib with Rituximab and Drug Combination for Older Adults with Untreated Diffuse Large B-Cell Lymphoma

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Acalabrutinib

Contact Research Centre

Find therapies in clinical trials near you – page 6

182 trials match your criteria

C3 glomerulopathy

Study on Long-Term Effects of Iptacopan in Patients with C3 Glomerulopathy or Idiopathic Immune-Complex Membranoproliferative Glomerulonephritis

Myelofibrosis

Study on Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis and Suboptimal Response to Ruxolitinib

Sepsis

Study on Early Clarithromycin Treatment to Prevent Sepsis in Patients with Community-Acquired Pneumonia

Chronic kidney disease+1

Study on the Long-Term Safety of Finerenone with ACE Inhibitors or ARBs for Children and Young Adults with Chronic Kidney Disease and Proteinuria

Plasma cell myeloma refractory

Study Comparing Elranatamab to Drug Combinations for Patients with Relapsed/Refractory Multiple Myeloma After Anti-CD38 Therapy

Myelofibrosis+1

Study on the Effectiveness and Safety of Selinexor for Patients with Myelofibrosis and Moderate Thrombocytopenia Who Have Not Used JAK Inhibitors

Chronic lymphocytic leukaemia+1

Study Comparing Nemtabrutinib, Ibrutinib, and Acalabrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Thalassaemia beta+2

Study of SP-420 for Patients with Transfusion-Dependent Alpha or Beta Thalassemia

Glomerulonephritis membranoproliferative

Study on the Effects of Iptacopan in Patients with Idiopathic Membranoproliferative Glomerulonephritis (IC-MPGN)

Post-acute COVID-19 syndrome

Study on Anakinra for Patients with Long COVID and Ongoing Respiratory Symptoms

Transitional cell cancer of the renal pelvis and ureter

Study of Sacituzumab Govitecan for Patients with Advanced or Metastatic Bladder Cancer

Double hit lymphoma+7

Study on Acalabrutinib with Rituximab and Drug Combination for Older Adults with Untreated Diffuse Large B-Cell Lymphoma

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.